A new cough syrup containing Guaifenesin/Hydrocodone is introduced. What controlled schedule shall it be assigned to?

The correct assignment of a cough syrup containing Guaifenesin/Hydrocodone to a controlled schedule is influenced by the specific components of the medication and their regulatory classifications. Hydrocodone, which is an opioid agonist, is classified as a Schedule II controlled substance due to its potential for abuse, addiction, and dependence.

In this formulation, Guaifenesin serves as an expectorant and is not controlled, but the presence of Hydrocodone is the determining factor for the overall classification of the product. The combination of Guaifenesin with Hydrocodone does not alter Hydrocodone's schedule, as the primary active ingredient that dictates the controlled substance categorization remains Hydrocodone itself.

Thus, any medication containing Hydrocodone, regardless of the other ingredients, is assigned to Schedule II. This classification reflects the stringent regulations associated with prescribing and dispensing such medications, which are designed to mitigate the risks of abuse and misuse associated with opioids. Recognizing the importance of maintaining careful control over substances with the potential for addiction helps ensure public safety while allowing access to necessary medical treatments under appropriate conditions.